8 registrations that name ginger as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 8 registrations
Status
Phase
3US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 8 registrations
RecruitingNCT06817018
Ginger Root Extract for Sciatic Pain Individuals
Phase 2
Leslie Shen
About 80 people
Started Jul 1, 2025
In plain words A Phase 2 study of ginger in people 18 to 85, run by Leslie Shen. It plans to enroll about 80 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 85. Conditions: Neuropathic Pain; Sciatic Pain.
18-85 years old men and women with BMI < 25 or ≥ 30 kg/m2
low back or gluteal pain radiating into leg(s) past the knee (sciatica) with pain duration of at least 3 months (chronic sciatica)
pain scale > 3 out of 10 (0=no pain,10=worst pain imaginable) during the past 24 hours
willingness to accept randomization.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Placebo; Ginger
Registered summary
Neuropathic pain affects the quality of life of many Americans. Non-pharmacological strategies such as bioactive compounds in foods are being explored as therapeutics but can also serve as tools to better understand pain mechanisms. The previous study reported that ginger root extract supplementation palliated pain-spectrum behaviors in animals with neuropathic pain via the microbiota-gut-brain axis. The full summary is on the listing.
Where, as registered
2 US sites in 1 state.
RecruitingNCT07190495
Ginger to Prevent Nausea and Vomiting After Laparoscopic Cholecystectomy
Phase 4
University Tunis El Manar
About 102 people
Started Jul 5, 2025
In plain words A Phase 4 study of ginger in people 18 and older, run by University Tunis El Manar. It plans to enroll about 102 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Postoperative Nausea and Vomiting; Laparoscopic Cholecystectomy.
Age ≥ 18 years.
Scheduled for elective laparoscopic cholecystectomy under general anesthesia.
American Society of Anesthesiologists (ASA) physical status I-III.
Able to understand the study procedures and provide written informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
Ginger; Placebo
Registered summary
This study aims to evaluate whether preoperative oral administration of ginger (800 mg, given 2 hours before surgery) reduces the incidence and severity of postoperative nausea and vomiting (PONV) within the first 24 hours after laparoscopic cholecystectomy.
Where, as registered
No US site; Tunisia (1).
RecruitingNCT07437222
Effect of Ginger Capsules on Inflammation, Oxidative Stress, and Endothelial Function
No phase
Ana Mª Garcia Munoz
About 50 people
Started Mar 2, 2026
In plain words A study of ginger in people 23 to 65, run by Ana Mª Garcia Munoz. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 23 to 65. Conditions: Inflammation Biomarkers; Oxidative Stress; Cardiometabolic Risk Factors.
Male and female participants.
Age between 23 and 65 years.
Body mass index (BMI) > 27.5 kg/m².
Absence of diagnosed chronic diseases.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Ginger supplement; Placebo capsules without ginger
Registered summary
Randomized, double-blind, parallel, placebo-controlled clinical trial designed and conducted to evaluate the effect of daily consumption of ginger, on parameters related to inflammation, oxidative stress, and endothelial damage in adults with excess adiposity.
Where, as registered
No US site; Spain (1).
Not yet recruitingNCT07792395
Ginger's Therapeutic Potential in Asthma
Phase 2
Emily DiMango, MD
About 32 people
Starts Nov 2026 (estimated)
In plain words A Phase 2 study of ginger in people 18 and older, run by Emily DiMango, MD. It plans to enroll about 32 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Asthma.
Adults aged 18 years or older with mild to severe persistent asthma as defined by NIH National Asthma Education and Prevention Program (NAEPP) guidelines, with asthma that is not optimally controlled despite current use of inhaled…
Treatment with inhaled corticosteroids (ICS), with or without long-acting beta-agonists/long-acting muscarinic antagonists and montelukast.
Physician-diagnosed asthma confirmed by history/report, pulmonary function testing with FEV1 ≥60% predicted or ≥1.5 L, and methacholine testing with baseline methacholine PD20 <16 mg/mL if taking ICS or <8 mg/mL if not taking ICS at Visit…
Non-smoker of tobacco, e-cigarettes, or marijuana for ≥1 year. Nicotine patch or gum is permitted.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Ginger Extract; Placebo
Registered summary
Primary Objective: The primary endpoint is a clinically significant improvement in tolerance to inhaled methacholine (PD20). Secondary Objectives: 1) To determine if oral daily ginger extract intake - decreases fractional excretion of nitric oxide; decreases blood eosinophilia; decreases asthma-associated cytokines in serum; decreases medium chain fatty acids; improves asthma symptoms; and 2) Establish pharmacokinetic parameters of biologically active components of ginger in adult asthmatics.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07315412
Chewing Gum Flavors to Reduce Postoperative Nausea and Vomiting After PIPAC
No phase
Fenerbahce University
About 75 people
Starts Dec 10, 2025 (estimated)
In plain words A study of ginger in people 18 to 80, run by Fenerbahce University. It plans to enroll about 75 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Postoperative Nausea and Vomiting (PONV); Peritoneal Metastases From Colorectal Cancer; Intraperitoneal Chemotherapy.
Adults aged 18 years or older undergoing Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).
Able to communicate, understand study instructions, and provide written informed consent.
No known allergy or intolerance to ginger, mint, or cinnamon.
Able and willing to chew gum for 15 minutes.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Ginger-Mint Chewing Gum; Cinnamon Chewing Gum
Registered summary
This randomized controlled clinical trial aims to evaluate the effectiveness of chewing gum with different natural flavors in reducing postoperative nausea and vomiting (PONV) following Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Adult patients undergoing PIPAC will be randomly assigned to one of three groups: (1) ginger-mint flavored gum, (2) cinnamon flavored gum, or (3) control group with standard postoperative care only. Participants in the intervention arms will chew one piece of gum for 15 minutes in the post-anesthesia care unit (PACU). The full summary is on the listing.
Where, as registered
No US site; Turkey (Türkiye) (1).
Not yet recruitingNCT07595640
Effect of Ginger on Heavy Menstrual Bleeding in Women With Coagulation Disorders
Early phase 1
University of Valladolid
About 74 people
Starts Feb 1, 2028 (estimated)
In plain words An early phase 1 study of ginger in female participants 18 to 45, run by University of Valladolid. It plans to enroll about 74 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 45. Conditions: Women With Coagulation Disorders.
Women of childbearing age with coagulopathies, -Regular menstrual cycles, -heavy menstrual bleeding (demonstrated by recording 3 menstrual cycles), -who voluntarily wish to participate in the study.
The exclusion criteria are on the listing.
What it tests, as registered
Ginger; Placebo
Registered summary
The GINGER-BLEED study is a randomized, double-blind, placebo-controlled clinical trial evaluating the effect of ginger powder on heavy menstrual bleeding in women with coagulopathies. This type of bleeding, defined as a loss of more than 80 ml per cycle, significantly affects women's quality of life, causing anemia, pain, and social limitations. Although conventional treatments exist, they can cause adverse effects, especially in women with coagulation disorders. The hypothesis is that administering 750 mg of ginger daily for six months can reduce menstrual bleeding. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT06772974
Tablet Ginger Versus Tablet Doxylamine Succinate in Control of Nausea and Vomiting in Pregnancy
No phase
Nawaz Sharif Medical College
About 66 people
Starts Jan 15, 2025 (estimated)
In plain words A study of ginger in female participants 18 to 49, run by Nawaz Sharif Medical College. It plans to enroll about 66 people at 1 site, none in the US.
Attending OPD with signs and symptoms of nausea and vomiting with ultrasound confirmed pregnancy
1st and 2nd gravida
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Doxylamine Succinate USP; Ginger
Registered summary
Nausea and vomiting are common GI symptoms of pregnancy. Multiple managing options have been used for NVP. Doxylamine succinate is used as first line treatment for NVP despite that alternative modalities such as ginger extracts and tablets is being explored. This RCT will be conducted after taking ethical approval and informed consent, in Department of Gynecology, Aziz Bhatti Shaheed teaching hospital, Gujrat. Patients will be divided into two equal groups. One group will receive tablet ginger while other group will receive Doxylamine succinate tablets. The full summary is on the listing.
Where, as registered
No US site; Pakistan (1).
Not yet recruitingNCT07596979
Ginger in the Modulation of Inflammatory Cytokines and Oxidative Stress in Patients With Coronary Artery Disease
No phase
Universidade Federal Fluminense
About 50 people
Starts May 18, 2026 (estimated)
In plain words A study of ginger in people 18 and older, run by Universidade Federal Fluminense. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Coronary Artery Disease (CAD); Oxidative Stress; Inflammation.
Both sexes
Over 18 years of age;
Diagnosed with Coronary Artery Disease: confirmed by coronary angiography, coronary computed tomography angiography, or functional testing with ischemic load);
Participants who are asymptomatic or have angina limited to functional class III will be considered;
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Ginger; Placebo
Registered summary
The study aims to evaluate the effect of ginger supplementation on inflammatory cytokines and markers of oxidative stress in patients with Coronary Artery Disease (CAD). A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.